Example: Heart Attack

Search clinical trials for: BI 1356

Total 175 results

NCT02183493

Completed

Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects

Conditions: Healthy
NCT02173652

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Conditions: Healthy
NCT02183376

Completed

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Conditions: Hepatic Insufficiency
NCT02183532

Completed

Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers

Conditions: Healthy
NCT02183441

Completed

Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers

Conditions: Healthy
NCT00800683

Completed

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

Conditions: Diabetes Mellitus, Type 2
NCT02183506

Completed

Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers

Conditions: Healthy
NCT02183389

Completed

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Conditions: Healthy
NCT02183428

Completed

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Conditions: Healthy
NCT02183337

Completed

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Conditions: Healthy
NCT02175394

Completed

Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects

Conditions: Healthy
NCT00819091

Completed

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Conditions: Diabetes Mellitus, Type 2
NCT02442817

Completed

Linagliptin and Mesenchymal Stem Cells: A Pilot Study

Conditions: Schizophrenia
NCT02280174

Unknown status

Effect of Linagliptin on TRL Metabolism

Conditions: Type 2 Diabetes
NCT02183610

Completed

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

Conditions: Healthy
NCT02183402

Completed

Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers

Conditions: Healthy
NCT02183363

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Conditions: Healthy
NCT02173639

Completed

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Conditions: Healthy
NCT02183623

Completed

The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers

Conditions: Healthy
NCT02183350

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2
NCT02183298

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Conditions: Healthy
NCT02173665

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects

Conditions: Healthy
NCT02183311

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Conditions: Healthy
NCT00622284

Completed

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2
NCT02376075

Completed

Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria

Conditions: Arterial Hypertension; Albuminuria